Adaptable framework for cost-analyses in radiotherapy: Application to the cost of proton versus photon therapy for lung cancer in The Netherlands

Bradley M. Sugden, Willem J.A. Witlox, Bram L.T. Ramaekers, Djoya Hattu, Boy Vluggen, Judith van Loon, Maria Jacobs, Manuela A. Joore, Dirk K.M. De Ruysscher

Research output: Contribution to journalArticleScientificpeer-review

Abstract

BACKGROUND/PURPOSE: Proton radiation-therapy (PrT) may provide clinical benefit for lung cancer compared to photon radiation-therapy (PhT), however is more costly. Literature reporting costs for PrT, PhT, and comparisons thereof, particularly from a societal perspective, are scarce. This study aims to provide an adaptable framework to estimate PrT/PhT costs, demonstrated through application to lung cancer, from societal and healthcare perspectives.

METHODS: Dutch Costing Guidelines were followed to estimate costs from first referral to end of treatment. A parallel base-case was conducted whereby centre-specific inputs replaced general input parameters. Costs were calculated probabilistically using Monte Carlo simulations (10,000 iterations) and separated into three categories: healthcare (subdivided: personnel, non-personnel), patient/family, and costs in other sectors. Direct healthcare personnel costs were estimated using time-driven activity-based costing, allowing separation of non-fraction-dependant costs. Further sensitivity/scenario analyses were explored.

RESULTS: Fixed costs (guideline[centre-specific] analyses mean) from a societal perspective were €11,208[€12,299] for PrT and €9,651[€10,977] for PhT. Variable costs per fraction were €932[€798] for PrT and €265[€265] for PhT. Total cost ratio for PrT to PhT was 2.00[1.74] for 20 fraction schedules and 2.23[1.91] for 30 fractions. The greatest incremental cost driver category for PrT versus PhT was non-(direct)personnel healthcare costs (overheads, capital outlays).

CONCLUSION: An adaptable framework for probabilistic cost-analyses was developed. Results highlight cost disparities between PrT and PhT and serves to inform future cost-effectiveness analyses. Scenarios reveal potential for clinical experience and increased capacity to narrow differences. Parallel base-case analyses highlight cost disparities arising when utilising generic vs centre-specific inputs, and potential outcome differences between centres.

Original languageEnglish
Article number110832
JournalRadiotherapy and Oncology
Early online date8 Mar 2025
DOIs
Publication statusPublished - May 2025

Keywords

  • Cost-Analysis
  • Proton
  • Photon
  • Lung cancer
  • Adaptable
  • Framework
  • Societal perspective

Fingerprint

Dive into the research topics of 'Adaptable framework for cost-analyses in radiotherapy: Application to the cost of proton versus photon therapy for lung cancer in The Netherlands'. Together they form a unique fingerprint.

Cite this